<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <schemaVersion>X0202</schemaVersion>
<headerData>
    <submissionType>SCHEDULE 13G</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: SMITH%2DVAN VURST ANDREW -->
          <cik>0002147206</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <securitiesClassTitle>Common Stock, $0.001 par value (the "Common Stock")</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>09/30/2026</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001658678</issuerCik>
        <issuerName>BioStem Technologies, Inc.</issuerName>
        <issuerCusips>
          <issuerCusipNumber>090684200</issuerCusipNumber>
        </issuerCusips>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>2836 Center Port Circle</com:street1>
          <com:city>Pompano Beach</com:city>
          <com:stateOrCountry>FL</com:stateOrCountry>
          <com:zipCode>33064</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(d)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>Andrew Van Vurst</reportingPersonName>
      <citizenshipOrOrganization>X1</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>3854452.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>3854452.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>3854452.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>18.4</classPercent>
      <typeOfReportingPerson>IN</typeOfReportingPerson>
      <comments>(1) Based on 18,672,125 shares of Common Stock outstanding as of October 1, 2026, as reported in the Issuer's Registration Statement on Form S-1 filed on October 2, 2026, plus 2,314,643 shares issuable to the Reporting Person upon exercise or conversion of derivative securities exercisable within 60 days of September 30, 2026, computed in accordance with Rule 13d-3(d)(1)(i).</comments>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>BioStem Technologies, Inc.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>2836 Center Port Circle, Pompano Beach, Florida 33064.</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>Andrew Van Vurst (the "Reporting Person").</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>c/o BioStem Technologies, Inc., 2836 Center Port Circle, Pompano Beach, Florida 33064.</principalBusinessOfficeOrResidenceAddress>
        <citizenship>United States.</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>Y</notApplicableFlag>
      </item3>
      <item4>
        <amountBeneficiallyOwned>3,854,452 shares of Common Stock, consisting of: (i) 1,539,809 shares of Common Stock held directly; (ii) 2,250,000 shares of Common Stock issuable upon exercise of fully vested options with an exercise price of $2.00 per share expiring October 24, 2032; (iii) 56,872 shares of Common Stock issuable upon exercise of the vested portion of options to purchase 114,314 shares at $10.05 per share expiring March 17, 2035; (iv) 7,671 shares of Common Stock issuable upon exercise of the portion of options to purchase 23,246 shares at $10.05 per share expiring October 13, 2035 that vests on October 13, 2026; and (v) 100 shares of Common Stock issuable upon conversion of 100 Series A-1 Convertible Preferred Shares. The amount excludes restricted stock units covering an aggregate of 297,020 shares not scheduled to vest on or before November 29, 2026. The amount also excludes options to purchase 253,304 shares at $5.50 per share not scheduled to vest on or before November 29, 2026.</amountBeneficiallyOwned>
        <classPercent>18.4%. See footnote (1) to the cover page.</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>3,854,452</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>0</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>3,854,452</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>0</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>Y</notApplicableFlag>
      </item5>
      <item6>
        <notApplicableFlag>Y</notApplicableFlag>
      </item6>
      <item7>
        <notApplicableFlag>Y</notApplicableFlag>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>Y</notApplicableFlag>
      </item10>
    </items>
    <signatureInformation>
      <reportingPersonName>Andrew Van Vurst</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Andrew Van Vurst</signature>
        <title>Andrew Van Vurst</title>
        <date>11/10/2026</date>
      </signatureDetails>
    </signatureInformation>
  </formData>
</edgarSubmission>
